Your browser doesn't support javascript.
loading
Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
Timmerman, Axelle; Balcaen, Margot; Coopman, Vera; Degreef, Maarten; Pottie, Eline; Stove, Christophe P.
Afiliação
  • Timmerman A; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
  • Balcaen M; Belgian Early Warning System on Drugs, Unit Illicit drugs, Health information, Sciensano, Brussels, Belgium.
  • Coopman V; Eurofins Forensics Belgium, Bruges, Belgium.
  • Degreef M; Belgian Early Warning System on Drugs, Unit Illicit drugs, Health information, Sciensano, Brussels, Belgium.
  • Pottie E; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
  • Stove CP; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. christophe.stove@ugent.be.
Harm Reduct J ; 21(1): 127, 2024 07 01.
Article em En | MEDLINE | ID: mdl-38951904
ABSTRACT

BACKGROUND:

Since late 2019, fortification of 'regular' cannabis plant material with synthetic cannabinoid receptor agonists (SCRAs) has become a notable phenomenon on the drug market. As many SCRAs pose a higher health risk than genuine cannabis, recognizing SCRA-adulterated cannabis is important from a harm reduction perspective. However, this is not always an easy task as adulterated cannabis may only be distinguished from genuine cannabis by dedicated, often expensive and time-consuming analytical techniques. In addition, the dynamic nature of the SCRA market renders identification of fortified samples a challenging task. Therefore, we established and applied an in vitro cannabinoid receptor 1 (CB1) activity-based procedure to screen plant material for the presence of SCRAs.

METHODS:

The assay principle relies on the functional complementation of a split-nanoluciferase following recruitment of ß-arrestin 2 to activated CB1. A straightforward sample preparation, encompassing methanolic extraction and dilution, was optimized for plant matrices, including cannabis, spiked with 5 µg/mg of the SCRA CP55,940.

RESULTS:

The bioassay successfully detected all samples of a set (n = 24) of analytically confirmed authentic Spice products, additionally providing relevant information on the 'strength' of a preparation and whether different samples may have originated from separate batches or possibly the same production batch. Finally, the methodology was applied to assess the occurrence of SCRA adulteration in a large set (n = 252) of herbal materials collected at an international dance festival. This did not reveal any positives, i.e. there were no samples that yielded a relevant CB1 activation.

CONCLUSION:

In summary, we established SCRA screening of herbal materials as a new application for the activity-based CB1 bioassay. The simplicity of the sample preparation, the rapid results and the universal character of the bioassay render it an effective and future-proof tool for evaluating herbal materials for the presence of SCRAs, which is relevant in the context of harm reduction.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cannabis / Agonistas de Receptores de Canabinoides Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cannabis / Agonistas de Receptores de Canabinoides Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article